Table of Contents:

1 Executive Summary
2 Market Introduction
2.1 Scope of the Study
2.2 Research Objective
2.3 List of Assumptions
3 Research Methodology
3.1 Research Methodology - X-Linked Hypophosphatemia Market
3.2 Data Mining
3.3 Secondary Research
3.3.1 Data points received from the secondary research
3.4 Primary Research
3.4.1 Data points received from surgeons, & consulting physicians
3.4.2 Data points received from the manufacturer
3.5 Forecasting Techniques
3.6 Research Methodology for Market Size Estimation X-Linked Hypophosphatemia Market:
3.6.1 Assumptions
3.7 Data Triangulation
3.8 Validation
4 Market Dynamics
4.1 Overview
4.2 Drivers
4.2.1 Increasing Prevalence Rate of XLH
4.2.2 Growing Awareness about XLH
4.2.3 Increasing Research
4.2.4 Driver Impact Analysis
4.3 Restraints
4.3.1 Side-Effects Associated with Burosumab
4.3.2 High Cost of Burosumab
4.3.3 Limited Availability of Treatment Options
4.3.4 Restraint Impact Analysis
4.4 Opportunity
4.4.1 Recent Regulatory Approvals
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 Overview
5.1.2 R&D
5.1.3 Manufacturing
5.1.4 Distribution and Sales
5.1.5 Post-Sales Monitoring
5.2 Porter's Five Forces Model
5.2.1 Overview
5.2.2 Bargaining Power of Suppliers
5.2.3 Bargaining Power of Buyers
5.2.4 The threat of New Entrants
5.2.5 Threat of Substitutes
5.2.6 Intensity of Rivalry
6 Global X-Linked Hypophosphatemia Market, by Treatment
6.1 Introduction
6.2 Medication
6.3 Surgical or Orthopedic Treatment
7 Global X-Linked Hypophosphatemia Market, by End User
7.1 Introduction
7.2 Hospitals and Clinics
7.3 Research Centers
8 Global X-Linked Hypophosphatemia Market, by Region
8.1 Introduction
8.2 Americas
8.2.1 North America
8.2.1.1 US
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Germany
8.3.2 France
8.3.3 UK
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia-Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 South Korea
8.4.5 Australia
8.4.6 Rest of Asia-Pacific
8.5 RoW
9 Competitive landscape
9.1 Introduction
9.2 Key developments
10 Company Profiles
10.1 Ultragenyx Pharmaceutical
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Products/Services Offered
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.1.6 Key Strategies
10.2 Validus Pharmaceuticals LLC
10.2.1 Company Overview
10.2.2 Financial Overview
10.2.3 Products/Services Offered
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.2.6 Key Strategies
10.3 Prospec-Tany Technogene Ltd
10.3.1 Company Overview
10.3.2 Financial Overview
10.3.3 Products/Services Offered
10.3.4 Key Developments
10.3.5 SWOT Analysis
10.3.6 Key Strategies
10.4 Merck KGaA
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Products/Services Offered
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.4.6 Key Strategies
10.5 Zeria Pharmaceutical Co., Ltd
10.5.1 Company Overview
10.5.2 Financial Overview
10.5.3 Products/Services Offered
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.5.6 Key Strategies
10.6 Smith & Nephew
10.6.1 Company Overview
10.6.2 Financial Overview
10.6.3 Products/Services Offered
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.6.6 Key Strategies
10.7 Narang Medical Limited
10.7.1 Company Overview
10.7.2 Financial Overview
10.7.3 Products/Services Offered
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.7.6 Key Strategies
10.8 Eli Lilly and Company
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Products/Services Offered
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.8.6 Key Strategies
10.9 F. Hoffmann-La Roche Ltd
10.9.1 Company Overview
10.9.2 Financial Overview
10.9.3 Products/Services Offered
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.9.6 Key Strategies
10.1 Illumina, Inc.
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Products/Services Offered
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.10.6 Key Strategies
10.11 Biomedica Medizinprodukte GmbH
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Products/Services Offered
10.11.4 Key Developments
10.11.5 SWOT Analysis
10.11.6 Key Strategies
10.12 QIAGEN
10.12.1 Company Overview
10.12.2 Financial Overview
10.12.3 Products/Services Offered
10.12.4 Key Developments
10.12.5 SWOT Analysis
10.12.6 Key Strategies
11 Appendix
11.1 References
11.2 Related Reports